Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo Nodularis
A Phase 3, 52-Week, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab in Adult Subjects With Prurigo Nodularis Who Are Inadequately Controlled on Topical Therapies or Not Eligible for Topical Therapies
- Sex: Any
- Age: Adult (18 - 64), Older Adult (65+)
- Accepting Healthy People: No
- Type: Interventional / Therapeutic
- Trial Phase: Phase III
- Conditions Being Studied: Prurigo Nodularis
Study Purpose
The purpose of this research study is to evaluate the efficacy of rocatinlimab compared with placebo at week 24 on the patient-reported outcome measure of prurigo nodularis and overall clinical assessment score.
Who Can Participate
Participants 18 years and older with diagnosed with prurigo nodularis that has been present for at least 3 months may be eligible for this study.
Locations
UH Cleveland Medical Center
11100 Euclid Ave
Cleveland OH, 44106
- UH IRB: STUDY20240572
- StudyID: 2024-01492
- ClinicalTrials.gov: NCT06527404
Questions or concerns? We're here to help.
Non-cancer Trials: 1-833-78TRIAL or Contact Us Online
Cancer Trials: 1-800-641-2422